¿Por qué sube el precio de la acción de GSK?
Los alcistas dicen
Acquisition Strategy
The acquisition of efimosfermin is sound given that it expands GSK's hepatology portfolio, provides optionality to related diseases, and fits within GSK's BD strategy.
Pipeline Development
Key launches and pipeline catalysts over the next 12 months should build confidence in GSK's £40B sales target by 2031, the majority of which is from on-market products.
Product Development
The launch of depemokimab is another inflection point given the opportunity biologics have to further penetrate the respiratory market.
Product Launches
Blenrep's U.S. PDUFA and commercial launches will be key factors in achieving GSK's target.



